In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Eli Lilly and Company announced Tuesday it was investing more than $6 billion in a new manufacturing facility in Huntsville, Alabama. The next-generation synthetic medicine active pharmaceutical ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Dec 9 (Reuters) - Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing ...

A major pharmaceutical company is making an announcement on Tuesday regarding growth of biopharma innovation in the Rocket ...

Dec 10 (Reuters) - French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma ...

This is no reason to panic.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

The site is the third of four new facilities in the U.S. that the pharmaceutical company plans to announce, Eli Lilly said.